+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology; By Biomarker Type; By Cancer Type; By Application; By Regions - Segment Forecast, 2020-2027

  • ID: 5261838
  • Report
  • September 2020
  • Region: Global
  • 122 pages
  • Polaris Market Research

FEATURED COMPANIES

  • Abott Molecular
  • Boreal Genomics Inc
  • Foundation Medicine
  • Histogene X
  • Neogenomics Inc.
  • Qiagen N.V.
The global cancer/tumor profiling market size is expected to reach USD 15.32 billion by 2027, according to the study.

The report “Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology (Immunoassay, NGS, PCR, In Situ Hybridization, Microarray, Mass Spectrometry, Others); By Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma, Others); By Biomarker Type (Genomic Biomarkers, Protein Biomarkers, Others); By Application (Personalized Medicine, Diagnostics, Prognostics, Biomarker Discovery, Research); By Regions-Segment-Forecast, 2020-2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing demand for tumor profiling and diagnosis and therapy techniques is driven by oncologists. Increased use of biomarkers in tumor profiling and increasing use of next-generation cancer profiling sequencing methods are some of the main factors driving the growth of the tumor profiling market. Tumor profiling is used to evaluate the metabolism, properties, and mutations of the tumor that can assist discover effective therapies. Drugs that target these mutated kinases can be discovered and developed based on genetic modification. The profiling is considered a requirement to increase the sensitivity of kinases-focused medications because they rely on individual tumors genetic composition. Thus, these mutated profiles of DNA tumors help to create specific anticarcinogenic treatments.

Globally there is a rise in cancer patients every year. According to the WHO this disease is considered to be the second leading cause mortalities in the year 2019. It is also estimated that that 1 out of 6 deaths were due to cancer. WHO has marked that one third of deaths from this disease are due to 5 leading behavioral and dietary risks. The factors include high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, and alcohol use. Tobacco is one of the leading factors for the rise in the prevalence of cancer and mortalities that approximately 22%. According to WHO, in 2015, there were around 17.6 million cases related to cancer that increases to 18.1 million cases in 2018 and nearly 9.6 million mortalities. The rising number of patients is the major factor for the growth of global cancer/tumor profiling market.

Certified techniques have been identified that can reduce the time taken to identify tumors and stages of advancement along with improved support for cancer research. Moreover, major investments by major biotechnology companies for the development of new therapies and new techniques of drug design are being witnessed across countries. This has significantly driven market growth and is expected to sustain growth during the forecast period. Biomarkers play a significant part in the design of a drug regime for cancer patients by quickly developing gene profiling techniques and individualizing targeted therapies. Currently, genome based prognostic biomarkers can be used to prognosticate multiple kinds of cancer in the clinical phases. Researchers, however, contend that conversion difficulties are hindering the broad divide between the phase of biomarker discovery and their clinical conversion. The acquisition of tumor genomic data is seen as the most significant step in cancer prediction, diagnosis, and therapy.

Next Generation Sequencing (NGS) is a sophisticated technique for the sequence that can be used for accurate tumor DNA genomic sequencing. The interpreted data contribute much more quickly to the assessment of tumor purity and the magnitude of disease progression. The primary benefit of NGS is the complete exotic sequence which helps examine all protein-coding areas of the human genome. It also enables whole genome sequencing to be useful for analysis of protein coding and non-coding areas in the human genome. Such advances in technology are one of the primary drivers of global cancer/tumor profiling market.

Moreover, the growing demand for personalized medicine further provides substantial opportunities for the tumor profiling market. The personalized medicine is defined as typical care in the treatment that is customized as per an individual patient. There have been several types of research going on presently to develop personal medicine based on the patients. Several factors should be considered before providing personal medicine to a patient. Firstly, the doctors have to detect the type or the symptoms of cancer that can be developed in a patient. Detection is important for the surgeon or the doctor, to find the best suited therapy that can treat the person. For developing a personalized medicine tumor profiling need to be taken into account as these tests will eventually reveal the various conditions of the patients such as detection of the individual developing a specific type of disease.

The analyst has segmented the cancer tumor/profiling market on the basis of:

Cancer Tumor/Profiling Technology Outlook (Revenue, USD Million, 2016-2027)
  • Immunoassay
  • NGS
  • PCR
  • In Situ Hybridization
  • Microarray
  • Mass Spectrometry
  • Others
Cancer Tumor/Profiling Cancer Type Outlook (Revenue, USD Billion, 2016-2027)
  • Breast
  • Lung
  • Colorectal
  • Prostate
  • Melanoma
  • Others
Cancer Tumor/Profiling Biomarker Type Outlook (Revenue, USD Billion, 2016-2027)
  • Genomic Biomarkers
  • Protein Biomarkers
  • Others
Cancer Tumor/Profiling Application Outlook (Revenue, USD Billion, 2016-2027)
  • Personalized Medicine
  • Diagnostics
  • Prognostics
  • Biomarker Discovery
  • Research
Cancer Tumor/Profiling Regional Outlook (Revenue, USD Million, 2016-2027)
  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Asia Pacific
  • India
  • Japan
  • China
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Colombia
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Israel
  • UAE
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abott Molecular
  • Boreal Genomics Inc
  • Foundation Medicine
  • Histogene X
  • Neogenomics Inc.
  • Qiagen N.V.
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders

2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation

3. Cancer/tumor Profiling Market Insights
3.1. Cancer/tumor Profiling- Industry snapshot
3.2. Cancer/tumor Profiling market dynamics
3.2.1. Cancer/tumor Profiling- Market Forces
3.2.1.1. Cancer/tumor Profiling Market driver analysis
3.2.1.2. Cancer/tumor Profiling Market restraint/challenges analysis
3.2.1.3. Cancer/tumor Profiling Market opportunity analysis
3.3. Industry analysis - Porter's five force
3.3.1. Bargaining power of supplier
3.3.2. Bargaining power of buyer
3.3.3. Threat of substitute
3.3.4. Threat of new entrant
3.3.5. Degree of competition
3.4. Cancer/tumor Profiling market PEST analysis
3.5. Value Chain Analysis
3.6. Competitive Ranking Analysis, 2019

4. Cancer/tumor Profiling Market Size and Forecast by Transducer Frequency Range
4.1. Global Cancer/tumor Profiling market share by technology, 2019 & 2027
4.2. Immunoassay
4.2.1. Global Immunoassay market estimates and forecasts, 2016-2027 (USD Million)
4.2.2. Global Immunoassay market estimates and forecasts, by region, 2016-2027 (USD Million)
4.3. Next Generation Sequencing (NGS)
4.3.1. Global NGS market estimates and forecasts, 2016-2027 (USD Million)
4.3.2. Global NGS market estimates and forecasts, by region, 2016-2027 (USD Million)
4.4. Polymerase Chain Reaction (PCR)
4.4.1. Global PCR market estimates and forecasts, 2016-2027 (USD Million)
4.4.2. Global PCR market estimates and forecasts, by region, 2016-2027 (USD Million)
4.5. In Situ Hybridization
4.5.1. Global In Situ Hybridization market estimates and forecasts, 2016-2027 (USD Million)
4.5.2. Global In Situ Hybridization market estimates and forecasts, by region, 2016-2027 (USD Million)
4.6. Microarray
4.6.1. Global Microarray market estimates and forecasts, 2016-2027 (USD Million)
4.6.2. Global Microarray market estimates and forecasts, by region, 2016-2027 (USD Million)
4.7. Mass Spectrometry
4.7.1. Global Mass Spectrometry market estimates and forecasts, 2016-2027 (USD Million)
4.7.2. Global Mass Spectrometry market estimates and forecasts, by region, 2016-2027 (USD Million)
4.8. Other Technology
4.8.1. Global Other Technology market estimates and forecasts, 2016-2027 (USD Million)
4.8.2. Global Other Technology market estimates and forecasts, by region, 2016-2027 (USD Million)

5. Cancer/tumor Profiling Market Size and Forecast by Cancer Type
5.1. Global Cancer/tumor Profiling market share by cancer type, 2019 & 2027
5.2. Breast Cancer
5.2.1. Global breast cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
5.2.2. Global breast cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)
5.3. Lung Cancer
5.3.1. Global lung cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
5.3.2. Global lung cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)
5.4. Colorectal Cancer
5.4.1. Global colorectal cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
5.4.2. Global colorectal cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)
5.5. Prostate Cancer
5.5.1. Global prostate cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
5.5.2. Global prostate cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)
5.6. Melanoma Cancer
5.6.1. Global Melanoma cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
5.6.2. Global melanoma cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)
5.7. Other Cancer
5.7.1. Global other cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
5.7.2. Global other cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)

6. Cancer/tumor Profiling Market Size and Forecast by Biomarker Type
6.1. Global Cancer/tumor Profiling market share by biomarker type, 2019 & 2027
6.2. Genomic Biomarkers
6.2.1. Global genomic biomarkers cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
6.2.2. Global genomic biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)
6.3. Protein Biomarkers
6.3.1. Global protein biomarkers cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
6.3.2. Global protein biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)
6.4. Other Biomarkers
6.4.1. Global other biomarkers cancer/tumor profiling market estimates and forecasts, 2016-2027 (USD Million)
6.4.2. Global other biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016-2027 (USD Million)

7. Cancer/tumor Profiling Market Size and Forecast by Application
7.1. Global Cancer/tumor Profiling market share by application, 2019 & 2027
7.2. Diagnostics
7.2.1. Global Cancer/tumor Profiling market from diagnostics estimates and forecasts, 2016-2027 (USD Million)
7.2.2. Global Cancer/tumor Profiling from diagnostics market estimates and forecasts, by region, 2016-2027 (USD Million)
7.3. Prognostics
7.3.1. Global Cancer/tumor Profiling market from Prognostics estimates and forecasts, 2016-2027 (USD Million)
7.3.2. Global hard Cancer/tumor Profiling from Prognostics market estimates and forecasts, by region, 2016-2027 (USD Million)
7.4. Personalized Medicine
7.4.1. Global Cancer/tumor Profiling market from Personalized Medicine estimates and forecasts, 2016-2027 (USD Million)
7.4.2. Global hard Cancer/tumor Profiling from Personalized Medicine market estimates and forecasts, by region, 2016-2027 (USD Million)
7.5. Biomarker Discovery
7.5.1. Global Cancer/tumor Profiling market from Biomarker Discovery estimates and forecasts, 2016-2027 (USD Million)
7.5.2. Global hard Cancer/tumor Profiling from Biomarker Discovery market estimates and forecasts, by region, 2016-2027 (USD Million)
7.6. Research
7.6.1. Global Cancer/tumor Profiling market from Research estimates and forecasts, 2016-2027 (USD Million)
7.6.2. Global hard Cancer/tumor Profiling from Research market estimates and forecasts, by region, 2016-2027 (USD Million)

8. Cancer/tumor Profiling Market Size and Forecast by Region
8.1. Global cancer/tumor profiling market share by region, 2019 & 2027
8.2. North America
8.2.1. North America cancer/tumor profiling market by technology (USD Million), 2016-2027
8.2.2. North America cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.2.3. North America cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.2.4. North America cancer/tumor profiling market by application (USD Million), 2016-2027
8.2.5. U.S.
8.2.5.1. U.S. cancer/tumor profiling market by technology (USD Million), 2016-2027
8.2.5.2. U.S. cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.2.5.3. U.S. cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.2.5.4. U.S. cancer/tumor profiling market by application (USD Million), 2016-2027
8.2.6. Canada
8.2.6.1. Canada cancer/tumor profiling market by technology (USD Million), 2016-2027
8.2.6.2. Canada cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.2.6.3. Canada cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.2.6.4. Canada cancer/tumor profiling market by application (USD Million), 2016-2027
8.3. Europe
8.3.1. Europe cancer/tumor profiling market by technology (USD Million), 2016-2027
8.3.2. Europe cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.3.3. Europe cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.3.4. Europe cancer/tumor profiling market by application (USD Million), 2016-2027
8.3.5. Germany
8.3.5.1. Germany cancer/tumor profiling market by technology (USD Million), 2016-2027
8.3.5.2. Germany cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.3.5.3. Germany cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.3.5.4. Germany cancer/tumor profiling market by application (USD Million), 2016-2027
8.3.6. UK
8.3.6.1. UK cancer/tumor profiling market by technology (USD Million), 2016-2027
8.3.6.2. UK cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.3.6.3. UK cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.3.6.4. UK cancer/tumor profiling market by application (USD Million), 2016-2027
8.3.7. France
8.3.7.1. France cancer/tumor profiling market by technology (USD Million), 2016-2027
8.3.7.2. France cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.3.7.3. France cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.3.7.4. France cancer/tumor profiling market by application (USD Million), 2016-2027
8.3.8. Italy
8.3.8.1. Ital cancer/tumor profiling market by technology (USD Million), 2016-2027
8.3.8.2. Italy cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.3.8.3. Italy cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.3.8.4. Italy cancer/tumor profiling market by application (USD Million), 2016-2027
8.3.9. Spain
8.3.9.1. Spain cancer/tumor profiling market by technology (USD Million), 2016-2027
8.3.9.2. Spain cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.3.9.3. Spain cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.3.9.4. Spain cancer/tumor profiling market by application (USD Million), 2016-2027
8.3.10. Netherlands
8.3.10.1. Netherlands cancer/tumor profiling market by technology (USD Million), 2016-2027
8.3.10.2. Netherlands cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.3.10.3. Netherlands cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.3.10.4. Netherlands cancer/tumor profiling market by application (USD Million), 2016-2027
8.4. Asia Pacific
8.4.1. Asia Pacific cancer/tumor profiling market by technology (USD Million), 2016-2027
8.4.2. Asia Pacific cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.4.3. Asia Pacific cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.4.4. Asia Pacific cancer/tumor profiling market by application (USD Million), 2016-2027
8.4.5. China
8.4.5.1. China cancer/tumor profiling market by technology (USD Million), 2016-2027
8.4.5.2. China cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.4.5.3. China cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.4.5.4. China cancer/tumor profiling market by application (USD Million), 2016-2027
8.4.6. South Korea
8.4.6.1. South Korea cancer/tumor profiling market by technology (USD Million), 2016-2027
8.4.6.2. South Korea cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.4.6.3. South Korea cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.4.6.4. South Korea cancer/tumor profiling market by application (USD Million), 2016-2027
8.4.7. Japan
8.4.7.1. Japan cancer/tumor profiling market by technology (USD Million), 2016-2027
8.4.7.2. Japan cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.4.7.3. Japan cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.4.7.4. Japan cancer/tumor profiling market by application (USD Million), 2016-2027
8.4.8. India
8.4.8.1. India cancer/tumor profiling market by technology (USD Million), 2016-2027
8.4.8.2. India cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.4.8.3. India cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.4.8.4. India cancer/tumor profiling market by application (USD Million), 2016-2027
8.5. Latin America
8.5.1. Latin America cancer/tumor profiling market by technology (USD Million), 2016-2027
8.5.2. Latin America cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.5.3. Latin America cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.5.4. Latin America cancer/tumor profiling market by application (USD Million), 2016-2027
8.5.5. Brazil
8.5.5.1. Brazil cancer/tumor profiling market by technology (USD Million), 2016-2027
8.5.5.2. Brazil cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.5.5.3. Brazil cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.5.5.4. Brazil cancer/tumor profiling market by application (USD Million), 2016-2027
8.5.6. Mexico
8.5.6.1. Mexico cancer/tumor profiling market by technology (USD Million), 2016-2027
8.5.6.2. Mexico cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.5.6.3. Mexico cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.5.6.4. Mexico cancer/tumor profiling market by application (USD Million), 2016-2027
8.5.7. Colombia
8.5.7.1. Colombia cancer/tumor profiling market by technology (USD Million), 2016-2027
8.5.7.2. Colombia cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.5.7.3. Colombia cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.5.7.4. Colombia cancer/tumor profiling market by application (USD Million), 2016-2027
8.6. Middle East & Africa
8.6.1. MEA cancer/tumor profiling market by technology (USD Million), 2016-2027
8.6.2. MEA cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.6.3. MEA cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.6.4. MEA cancer/tumor profiling market by application (USD Million), 2016-2027
8.6.5. Saudi Arabia
8.6.5.1. Saudi Arabia cancer/tumor profiling market by technology (USD Million), 2016-2027
8.6.5.2. Saudi Arabia cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.6.5.3. Saudi Arabia cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.6.5.4. Saudi Arabia cancer/tumor profiling market by application (USD Million), 2016-2027
8.6.6. South Africa
8.6.6.1. South Africa cancer/tumor profiling market by technology (USD Million), 2016-2027
8.6.6.2. South Africa cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.6.6.3. South Africa cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.6.6.4. South Africa cancer/tumor profiling market by application (USD Million), 2016-2027
8.6.7. Israel
8.6.7.1. Israel cancer/tumor profiling market by technology (USD Million), 2016-2027
8.6.7.2. Israel cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.6.7.3. Israel cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.6.7.4. Israel cancer/tumor profiling market by application (USD Million), 2016-2027
8.6.8. UAE
8.6.8.1. UAE cancer/tumor profiling market by technology (USD Million), 2016-2027
8.6.8.2. UAE cancer/tumor profiling market by cancer type (USD Million), 2016-2027
8.6.8.3. UAE cancer/tumor profiling market by biomarker type (USD Million), 2016-2027
8.6.8.4. UAE cancer/tumor profiling market by application (USD Million), 2016-2027

9. Company Profiles
9.1. Abott Molecular
9.1.1. Overview
9.1.2. Financials
9.1.3. Product Benchmarking
9.1.4. Recent Developments
9.2. Agendia
9.2.1. Overview
9.2.2. Financials
9.2.3. Product Benchmarking
9.2.4. Recent Developments
9.3. Boreal Genomics Inc
9.3.1. Overview
9.3.2. Financials
9.3.3. Product Benchmarking
9.3.4. Recent Developments
9.4. BD Biosciences
9.4.1. Overview
9.4.2. Financials
9.4.3. Product Benchmarking
9.4.4. Recent Developments
9.5. Caris Life Sciences
9.5.1. Overview
9.5.2. Financials
9.5.3. Product Benchmarking
9.5.4. Recent Developments
9.6. F. Hoffmann-La Roche Ltd
9.6.1. Overview
9.6.2. Financials
9.6.3. Product Benchmarking
9.6.4. Recent Developments
9.7. Foundation Medicine
9.7.1. Overview
9.7.2. Financials
9.7.3. Product Benchmarking
9.7.4. Recent Developments
9.8. Genscript Biotech Corporation
9.8.1. Overview
9.8.2. Financials
9.8.3. Product Benchmarking
9.8.4. Recent Developments
9.9. Guardant Health, Inc.
9.9.1. Overview
9.9.2. Financials
9.9.3. Product Benchmarking
9.9.4. Recent Developments
9.10. Helomics Corporation
9.10.1. Overview
9.10.2. Financials
9.10.3. Product Benchmarking
9.10.4. Recent Developments
9.11. Histogene X
9.11.1. Overview
9.11.2. Financials
9.11.3. Product Benchmarking
9.11.4. Recent Developments
9.12. Hologic, Inc.
9.12.1. Overview
9.12.2. Financials
9.12.3. Product Benchmarking
9.12.4. Recent Developments
9.13. HTG Molecular Diagnostics, Inc.
9.13.1. Overview
9.13.2. Financials
9.13.3. Product Benchmarking
9.13.4. Recent Developments
9.14. Illumina, Inc.
9.14.1. Overview
9.14.2. Financials
9.14.3. Product Benchmarking
9.14.4. Recent Developments
9.15. Nanostring Technologies, Inc.
9.15.1. Overview
9.15.2. Financials
9.15.3. Product Benchmarking
9.15.4. Recent Developments
9.16. Neogenomics, Inc.
9.16.1. Overview
9.16.2. Financials
9.16.3. Product Benchmarking
9.16.4. Recent Developments
9.17. Omniseq
9.17.1. Overview
9.17.2. Financials
9.17.3. Product Benchmarking
9.17.4. Recent Developments
9.18. Perthera
9.18.1. Overview
9.18.2. Financials
9.18.3. Product Benchmarking
9.18.4. Recent Developments
9.19. Qiagen N.V.
9.19.1. Overview
9.19.2. Financials
9.19.3. Product Benchmarking
9.19.4. Recent Developments
9.20. Ribomed Biotechnologies, Inc.
9.20.1. Overview
9.20.2. Financials
9.20.3. Product Benchmarking
9.20.4. Recent Developments
9.21. Roche Molecular Systems Inc.
9.21.1. Overview
9.21.2. Financials
9.21.3. Product Benchmarking
9.21.4. Recent Developments
9.22. Sysmex Corporation
9.22.1. Overview
9.22.2. Financials
9.22.3. Product Benchmarking
9.22.4. Recent Developments
9.23. Tempus Labs
9.23.1. Overview
9.23.2. Financials
9.23.3. Product Benchmarking
9.23.4. Recent Developments
Note: Product cover images may vary from those shown
  • Abott Molecular
  • Agendia
  • Boreal Genomics Inc
  • BD Biosciences
  • Caris Life Sciences
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine
  • Genscript Biotech Corporation
  • Guardant Health Inc.
  • Helomics Corporation
  • Histogene X
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.
  • Illumina Inc.
  • Nanostring Technologies Inc.
  • Neogenomics Inc.
  • Omniseq
  • Perthera
  • Qiagen N.V.
  • Ribomed Biotechnologies Inc.
  • Roche Molecular Systems Inc.
  • Sysmex Corporation
  • Tempus Labs
Note: Product cover images may vary from those shown
Adroll
adroll